Journal of Inherited Metabolic Disease

, Volume 31, Issue 1, pp 67–72 | Cite as

Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias

Original Article



A significant percentage of patients with hyperphenylalaninaemia (HPA) due to primary deficiency of the phenylalanine hydroxylase enzyme (PAH) respond to a dose of tetrahydrobiopterin (BH4) with an increased rate of phenylalanine (Phe) disposal. The effect is exploited therapeutically, with some patients on BH4 even tolerating a normal diet.


Classification of the Phe blood level response to a BH4 load by percentage reduction (PR) suffers from loss of information: only part of usually more extensive test data is used, and PR values for different times after load cannot be compared directly. Calculation of half-life (t1/2) of blood Phe is proposed as an alternative. This classic measure unifies interpretation of tests of different duration (e.g. 8 or 15 h). t1/2 subsumes first-order formation of tyrosine, of Phe metabolites, and renal Phe excretion; zero-order net protein synthesis can be neglected during short-time tests.


t1/2 is easily and robustly obtained by fit-ting the total set of (3–4) data points to a log-linear regression.


The advantage of calculating t1/2 is exemplified by the analysis of selected published data. The results clearly speak in favour of an 8 h test period because so-called ‘slow’ responders could also be detected within this time window and because tests of longer duration are less reliable kinetically. Sequential Phe and Phe/BH4 loading tests appear advantageous because the ‘natural’ t1/2 (without supplementation of BH4) is not normally known beforehand.


With t1/2 as a reliable parameter of BH4 responsiveness, therapeutic decisions would be more rational and genotype–phenotype analysis may also profit.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bartholomé K (1974) Letter: A new molecular defect in phenylketonuria. Lancet 2 (7896): 1580.PubMedCrossRefGoogle Scholar
  2. Bernegger C, Blau N (2002) High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002. Mol Genet Metab 77: 304–313.PubMedCrossRefGoogle Scholar
  3. Bélanger-Quintana A, Garcia MJ, Castro M, et al (2005) Spanish BH4-responsive phenylalanine hydoxylase-deficient patients: Evolution of seven patients on long-term treatment with tetrahydrobiopterin. Mol Gen Metab 86(Supplement 1): S61–S66.CrossRefGoogle Scholar
  4. Blau N, Erlandsen H (2004) The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 82: 101–111.PubMedCrossRefGoogle Scholar
  5. Boneh A, Francis DM, Humphrey M, et al (2006) Three-year audit of the hyperphenylalaninaemia/phenylketonuria spectrum in Victoria. J Pediatr Child Health 42: 496–498.CrossRefGoogle Scholar
  6. Curtius HC, Niederwieser A, Viscontini M, et al (1979) Atypical phenylketonuria due to tetrahydrobiopterin deficiency. Diagnosis and treatment with tetrahydrobiopterin, dihydrobiopterin and sepiapterin. Clin Chim Acta 93: 251–262.PubMedCrossRefGoogle Scholar
  7. Danks DM, Bartholomé K, Clayton BE, et al (1978) Malignant hyperphenylalaninaemia – Current status (June 1977). J Inherit Metab Dis 1: 49–53.PubMedCrossRefGoogle Scholar
  8. Danks DM, Cotton RGH, Schlesinger P (1979) Diagnosis of malignant hyperphenylalaninemia. Arch Dis Child 54: 329–330.PubMedCrossRefGoogle Scholar
  9. Desviat LR, Pérez B, Bèlanger-Quintana A, et al (2004) Tetrahydrobiopterin responsiveness: results of the BH4 loading test in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab 83: 157–162.PubMedCrossRefGoogle Scholar
  10. Erlandsen H, Pey AL, Gámez A, et al (2004) Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA 101: 16903–16908.PubMedCrossRefGoogle Scholar
  11. EMEA: European Medicines Agency, Committee for Orphan Medicinal Products (29 May 2007) Public summary of positive opinion for orphan designation of tetrahydrobiopterin for the treatment of hyperphenylalaninemia. Doc.Ref.: EMEA/COMP/258/04 Rev. 2.Google Scholar
  12. Fiege B, Blau N (2007) Assessment of tetrahydrobiopterin (BH4) responsiveness in phenylketonuria. J Pediatr 150: 627–630.PubMedCrossRefGoogle Scholar
  13. Fiege B, Bonafé L, Ballhausen D, et al (2005) Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: A pilot study. Mol Genet Metab 86: S91–S95.PubMedCrossRefGoogle Scholar
  14. Fiori L, Fiege B, Riva E, et al (2005) Incidence of BH4-responsiveness in phenylalanine-hydroxylase-deficient Italian patients. Mol Genet Metab 86: S67–S74.PubMedCrossRefGoogle Scholar
  15. Habich MS (2006) Pharmakologische Therapie der Phenylketonurie durch Defekt der Phenylalaninhydroxylase mit Tetrahydrobiopterin: Effekt auf Metabolite, in vivo Enzymaktivität und Proteintoleranz. Med. Thesis, Ludwig-Maximilian-University, Munich.Google Scholar
  16. Kure S, Hou DC, Ohura T, et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135: 375–378.PubMedCrossRefGoogle Scholar
  17. Langenbeck U, Wendel U (1997) Kinetic analysis of phenylalanine disposal in phenylalanine hydroxylase (PAH) deficiency. Int Pediatr 12: 19–22.Google Scholar
  18. Langenbeck U, Zschocke J, Wendel U, Hönig V (2001) Modelling the phenylalanine blood level response during treatment of phenylketonuria. J Inherit Metab Dis 24: 805–814.PubMedCrossRefGoogle Scholar
  19. Leatherbarrow RJ (1987) ENZFITTER. A Non-linear Regression Data Analysis Program for the IBM PC (and True Compatibles). Cambridge, UK: Elsevier-BIOSOFT.Google Scholar
  20. Lindner M, Steinfeld R, Burgard P, et al (2003) Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 21: 400 (Mutation in brief #588).PubMedCrossRefGoogle Scholar
  21. Muntau AC, Röschinger W, Habich M, et al (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med 347: 2122–2132.PubMedCrossRefGoogle Scholar
  22. Niederwieser A, Ponzone A, Curtius H-Ch (1985) Differential diagnosis of tetrahydrobiopterin deficiency. J Inherit Metab Dis 8(Supplement 1): 34–38.PubMedCrossRefGoogle Scholar
  23. Porta F, MussaA, Ferraris S, et al (2007) ‘Responsiveness’ and unresponsiveness to BH4 of PAH deficiency. J Inherit Metab Dis 30(Supplement 1): 16.Google Scholar
  24. Rey F, Blandin-Savoja F, Rey J (1979) Kinetics of phenylalanine disappearance after intra-venous load in phenylketonuria and its variants. Pediatr Res 13: 21–25.PubMedCrossRefGoogle Scholar
  25. Ritschel WA (1982) Handbook of Basic Pharmakokinetics, 2nd edn. Hamilton, IL: Drug Intelligence Publications.Google Scholar
  26. Rosenberg LE (1976) Vitamin-responsive inherited metabolic disorders. Adv Hum Genet 6: 1–74.PubMedGoogle Scholar
  27. Schadewaldt P, Dalle-Feste C, Langenbeck U, Wendel U (1991) Oral l-alloisoleucine loading studies in healthy subjects and in patients with maple syrup urine disease. Pediatr Res 30: 430–434.PubMedCrossRefGoogle Scholar
  28. Shintaku H, Kure S, Ohura T, et al (2004) Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr Res 55: 425–430.PubMedCrossRefGoogle Scholar
  29. Smith I, Lloyd J (1974) Proceedings: Atypical phenylketonuria accompanied by severe progressive neurological illness unresponsive to dietary treatment. Arch Dis Child 49: 245.PubMedGoogle Scholar
  30. Snyderman SE, Norton PM, Roitman E, Holt LE Jr (1964) Maple syrup urine disease, with particular reference to dietotherapy. Pediatrics 34: 454–472.PubMedGoogle Scholar
  31. Steinfeld R, Kohlschütter A, Zschocke J, Lindner M, Ullrich K, Lukacs Z (2002) Tetrahydrobiopterin monotherapy for phenylketonuria patients with common mild mutations. Eur J Pediatr 161: 403–405.PubMedCrossRefGoogle Scholar
  32. Trefz FK, Aulehla-Scholz C, Blau N (2001) Successful treatment of phenylketonuria with tetrahydrobiopterin. Eur J Pediatr 160: 315.PubMedCrossRefGoogle Scholar
  33. Trefz F, Burton B, Longo N, et al (2007) The effect of sapropterin dihydrochloride (tetrahydrobiopterin or 6R-BH4) treatment on phenylalanine (Phe) tolerance in children with phenylketonuria controlled on a Phe-restricted diet. J Inherit Metab Dis 30(Supplement 1): 17.Google Scholar
  34. Zurflüh MR, Fiori L, Fiege B, et al (2006) Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency. J Inherit Metab Dis 29: 725–731.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2008

Authors and Affiliations

  1. 1.Institute of Human GeneticsUniversity HospitalFrankfurt/MainGermany

Personalised recommendations